Dementia Associated With Alzheimer's Disease - Pipeline Insight, 2024

This “Dementia Associated With Alzheimer’s Disease - Pipeline Insight, 2024” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Dementia Associated With Alzheimer’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Dementia Associated With Alzheimer’s Disease: Understanding

Dementia Associated With Alzheimer’s Disease: Overview

Dementia is a general term used to describe a significant decline in cognitive ability that interferes with a person's activities of daily living. Alzheimer disease (AD) is the most prevalent type of dementia, accounting for at least two-thirds of cases in individuals aged 65 and older. AD is a neurodegenerative condition with insidious onset and progressive impairment of behavioral and cognitive functions. These functions include memory, comprehension, language, attention, reasoning, and judgment. While AD does not directly cause death, it substantially raises vulnerability to other complications, which can eventually lead to a person's death.

Diagnosing dementia associated with Alzheimer's disease typically involves a comprehensive assessment that includes medical history, cognitive testing, physical and neurological exams, and, if necessary, brain imaging. Doctors first rule out other potential causes of memory loss and cognitive decline, such as vitamin deficiencies or thyroid problems.

Cognitive tests assess memory, problem-solving skills, and language abilities to detect patterns consistent with Alzheimer’s. Neuroimaging, like MRI or CT scans, may be used to identify brain changes such as atrophy in specific areas. Advanced tests, including PET scans or cerebrospinal fluid analysis, can detect biomarkers associated with Alzheimer’s, providing more definitive evidence.

There is no known cure for Alzheimer’s disease. It is not possible to reverse the death of brain cells. Treatments can, however, relieve its symptoms and improve quality of life for the person and their family and caregivers. Drugs called cholinesterase inhibitors can ease cognitive symptoms, including memory loss, confusion, altered thought processes, and judgment problems.

They improve neural communication across the brain and slow the progress of these symptoms. Three common drugs with Food and Drug Administration (FDA) approval to treat these symptoms of Alzheimer’s disease are: donepezil (Aricept), to treat all stages; galantamine (Razadyne), to treat mild-to-moderate stages; rivastigmine (Exelon), to treat mild-to-moderate stages.

"Dementia Associated With Alzheimer’s Disease- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dementia Associated With Alzheimer’s Disease pipeline landscape is provided which includes the disease overview and Dementia Associated With Alzheimer’s Disease treatment guidelines. The assessment part of the report embraces, in depth Dementia Associated With Alzheimer’s Disease commercial assessment and clinical assessment of the pipeline products under development.

In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dementia Associated With Alzheimer’s Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Dementia Associated With Alzheimer’s Disease R&D. The therapies under development are focused on novel approaches to treat/improve Dementia Associated With Alzheimer’s Disease.

Dementia Associated With Alzheimer’s Disease Emerging Drugs Chapters

This segment of the Dementia Associated With Alzheimer’s Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Dementia Associated With Alzheimer’s Disease Emerging Drugs

NE3107: BioVie

NE3107 is an orally available small molecule with potential anti-inflammatory and insulin-sensitizing properties that can cross the blood-brain barrier. It was originally developed by NeurMedix and acquired by BioVie in April. The experimental molecule works by blocking the activation of two major regulators of inflammatory pathways: extracellular signal regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB).

NFκB is activated by amyloid beta and tau - two proteins that form toxic clumps that contribute to Alzheimer’s - and by the pro-inflammatory molecules that it stimulates, leading to chronic inflammation. NE3107 was found to have no immunosuppressive effects and to block ERK- and NF-κB-induced inflammation without suppressing their functions involved in maintaining overall balance, such as insulin signaling and nerve cell growth and survival. Currently, the drug is in Phase III stage of development for the treatment of Alzheimer Disease.

KarXT: Karuna Therapeutics

KarXT, a combination of xanomeline and trospium, is an investigational treatment developed by Karuna Therapeutics, primarily aimed at addressing psychosis associated with Alzheimer's disease (AD) and schizophrenia. KarXT functions as a muscarinic receptor agonist, specifically targeting the M1 and M4 muscarinic acetylcholine receptors. Xanomeline activates these receptors, which are crucial for cognitive processes such as learning and memory. Trospium, on the other hand, is included to mitigate peripheral side effects associated with xanomeline, such as nausea and vomiting, by preventing its action on muscarinic receptors outside the brain. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Dementia Associated With Alzheimer’s Disease.

Simufilam: Cassava Sciences

Simufilam (formerly known as PTI-125) is an investigational drug being developed by Cassava Sciences. It targets an altered form of filamin A (FLNA), a protein implicated in the disease's pathology. Unlike traditional Alzheimer's treatments that focus on clearing amyloid plaques, simufilam works by stabilizing FLNA, thereby potentially reducing neuroinflammation and cognitive decline associated with the disease. Currently, the drug is in the Phase III stage of development to treat Dementia Associated With Alzheimer’s Disease.

CT-1812: Cognition Therapeutics

Cognition Therapeutics isdeveloping CT1812, an oral, brain-penetrant, small molecule therapeutic, which has been shown to protect neurons and synapses by preventing the binding of toxic oligomers. CT1812 acts as a neuroprotective agent both by shielding neurons and synapses from oligomer binding and by preventing oligomers from attaching to synapses in the first place. CT1812 may help mitigate the neurotoxic effects, slowing cognitive decline and progression of Alzheimer’s disease. Currently, the drug is in the Phase II stage of development to treat Alzheimer’s-disease.

CM383: KeyMed Biosciences

CM383 is an investigational drug being developed for the treatment of Alzheimer's disease. It is a small molecule designed to target the underlying mechanisms of the disease, specifically by modulating the immune response and reducing neuroinflammation, which are key factors in Alzheimer's pathology. CM383 works by targeting the immune system's response to amyloid-beta plaques, which are characteristic of Alzheimer's disease. It aims to enhance the brain's ability to clear these plaques and improve neuronal health. This approach is distinct from many traditional Alzheimer's treatments that primarily focus on amyloid plaque reduction or cholinergic modulation. Currently, the drug is in the Phase I stage of development to treat Alzheimer’s-disease.

Dementia Associated With Alzheimer’s Disease: Therapeutic Assessment

This segment of the report provides insights about the different Dementia Associated With Alzheimer’s Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Dementia Associated With Alzheimer’s Disease

• There are approx. 80+ key companies which are developing the therapies for Dementia Associated With Alzheimer’s Disease. The companies which have their Dementia Associated With Alzheimer’s Disease drug candidates in the most advanced stage, i.e. Phase III include, BioVie, Karuna Therapeutics, and Cassava Sciences.

Phases

The report covers around 100+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Dementia Associated With Alzheimer’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Dementia Associated With Alzheimer’s Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dementia Associated With Alzheimer’s Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dementia Associated With Alzheimer’s Disease drugs.

Dementia Associated With Alzheimer’s Disease Report Insights

• Dementia Associated With Alzheimer’s Disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Dementia Associated With Alzheimer’s Disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Dementia Associated With Alzheimer’s Disease drugs?
• How many Dementia Associated With Alzheimer’s Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dementia Associated With Alzheimer’s Disease?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Dementia Associated With Alzheimer’s Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Dementia Associated With Alzheimer’s Disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• BioVie
• Karuna Therapeutics
• Cassava Sciences, Inc.
• Cognition Therapeutics
• Alector
• TrueBinding
• KeyMed Biosciences
• Alzinova
• AriBio Co., Ltd.
• Eli Lilly & Co.
• Cognition Therapeutics
• AbbVie Inc.
• Allyx Therapeutics, Inc.
• Eisai Inc.
• Shanghai Hengrui Pharmaceutical Co., Ltd.

Key Products

• NE3107
• KarXT
• Simufilam
• CT-1812
• AL002
• TB 006
• CM383
• ALZ 101
• AR1001
• LY3372689
• CT1812
• ABBV-916
• ALX-001
• E2814
• VT301

This product will be delivered within 3-5 business days.